Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101

Ernexa Therapeutics (Nasdaq: ERNA) released a Virtual Investor KOL Connect segment featuring Chief Scientific Officer Dr. Robert Pierce discussing ovarian cancer, treatment limitations, and the company’s approach.

Rhea-AI Summary

Ernexa Therapeutics (Nasdaq: ERNA) released a Virtual Investor KOL Connect segment featuring Chief Scientific Officer Dr. Robert Pierce discussing ovarian cancer, treatment limitations, and the company’s approach.

The company will also join a Virtual Investor Closing Bell event on May 13, 2026, highlighting preclinical ERNA-101 ovarian cancer data showing complete tumor elimination and 100% survival in models when combined with PD-1 blockade.

Positive

• Preclinical ERNA-101 data showed complete tumor elimination in ovarian cancer models with PD-1 blockade
• Preclinical ERNA-101 data showed 100% survival in ovarian cancer models with PD-1 blockade
• Investor-facing KOL segment increases visibility of ERNA-101’s ovarian cancer strategy

Negative

• None.

Argus May 11 session

-4.25% close to close Open Argus

Details

News Market Reaction – ERNA

In the May 11 session, ERNA declined 4.25%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement extends prior ERNA-101 preclinical data by framing the ovarian cancer landscape th...

Analysis

This announcement extends prior ERNA-101 preclinical data by framing the ovarian cancer landscape through a KOL-led discussion and highlighting 100% survival and complete tumor elimination in combination with PD-1 blockade. It builds on the strong reaction to the May 6, 2026 data release. Against a backdrop of recent financings, a reverse split, and an effective $50,000,000 shelf, future updates on clinical transition and funding will be key metrics to watch.

Key Figures

Survival rate: 100% survival Tumor response: Complete tumor elimination Closing Bell time: 4:00 PM ET +1 more

Survival rate

100% survival

Preclinical ovarian cancer models for ERNA-101 plus PD-1 blockade

Tumor response

Complete tumor elimination

Preclinical ovarian cancer models for ERNA-101 plus PD-1 blockade

Closing Bell time

4:00 PM ET

Virtual Investor Closing Bell event on May 13, 2026

Event date

May 13, 2026

Virtual Investor Closing Bell event featuring ERNA-101 discussion

Historical Context

5 past events · Latest: May 06

5 events

1. May 06

   Preclinical data update

   24h Move

   +51.4%

   ERNA-101 plus PD-1 showed complete tumor clearance and 100% survival.

2. Apr 30

   Reverse stock split

   24h Move

   -21.2%

   1-for-25 reverse split to regain Nasdaq minimum bid compliance.

3. Mar 31

   Pipeline and financing

   24h Move

   +5.3%

   Outlined ERNA-101 trial timing plus $10.5M financing and 61% G&A reduction.

4. Feb 20

   Investor event

   24h Move

   -17.3%

   Announcement of participation in a Virtual Investor Closing Bell event.

5. Feb 06

   Dilutive offering

   24h Move

   -44.7%

   $10.5M best-efforts offering of stock and warrants at $0.50 per unit.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

kol, pd-1 blockade, tumor microenvironment, immunologically “cold” tumors

4 terms

kol technical

"Virtual Investor KOL Connect segment featuring Dr. Robert Pierce"

A KOL, or key opinion leader, is a trusted expert—often a leading physician, researcher, or specialist—whose views influence peers, clinical practice, and industry adoption of medical products or treatments. For investors, KOL endorsements or criticisms can sway adoption rates, regulatory perceptions, and market confidence much like a respected critic can affect demand for a new product, so monitoring KOL sentiment helps gauge commercial and clinical prospects.

pd-1 blockade medical

"100% survival in ovarian cancer models when combined with PD-1 blockade."

PD-1 blockade is a type of cancer immunotherapy that uses drugs to block the PD-1 protein on immune cells, removing a built-in “brake” so those cells can better recognize and attack tumors. For investors it matters because successful PD-1 blockade drugs can drive strong clinical results, large patient demand, regulatory approvals, and long-term revenue, while failures or safety issues can sharply affect a drug’s commercial prospects.

tumor microenvironment medical

"by reshaping the tumor microenvironment to support stronger immune responses."

The tumor microenvironment is the immediate area surrounding a cancer cell, made up of nearby cells, blood vessels, and support structures that influence how the cancer grows and spreads. It functions like a bustling neighborhood that can either help or hinder the tumor’s development. For investors, understanding changes in this environment can signal the effectiveness of treatments and potential shifts in a cancer-related market.

immunologically “cold” tumors medical

"the potential for ERNA-101 to address immunologically “cold” tumors"

Immunologically “cold” tumors are cancers that show little to no activity from the body’s immune cells inside the tumor microenvironment, meaning they don’t attract the immune “soldiers” that detect and attack abnormal cells. For investors, this matters because cold tumors are less likely to respond to many current immunotherapies, making them a key target for companies developing drugs or diagnostics that can turn “cold” tumors “hot” or otherwise improve treatment response and market opportunity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Moderated discussion with Chief Scientific Officer Dr. Robert Pierce on ovarian cancer and evolving treatment landscape 

Segment highlights significant unmet need in ovarian cancer and the potential of ERNA-101 to address limitations of current therapies

Access the segment here

Company to also participate in Virtual Investor Closing Bell event on May 13 featuring Sanjeev Luther and Dr. Robert Pierce

Register for the Closing Bell event here 

CAMBRIDGE, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the release of a Virtual Investor KOL Connect segment featuring Dr. Robert Pierce, Chief Scientific Officer of Ernexa.
  
As part of the segment, Dr. Pierce provides insight into the complexities of ovarian cancer, one of the most challenging malignancies to treat, and discusses the limitations of current therapeutic approaches. The discussion highlights the patient journey from diagnosis through treatment, emphasizing the persistent unmet need for more effective and durable treatment options.

Dr. Pierce also outlines the evolving treatment landscape and shares his perspective on how Ernexa is approaching ovarian cancer differently at the biological level. He discusses the Company’s lead product candidate, ERNA-101, and its potential to improve outcomes and enhance the patient experience compared to existing therapies.

The Virtual Investor KOL Connect segment featuring Ernexa Therapeutics is now available here.

In addition, Ernexa announced that Sanjeev Luther, President & Chief Executive Officer, and Dr. Robert Pierce, Chief Scientific Officer, will participate in a Virtual Investor Closing Bell event on Wednesday, May 13, 2026, at 4:00 PM ET.

As part of the event, Mr. Luther and Dr. Pierce will provide a corporate overview and discuss Ernexa’s recently announced preclinical ovarian cancer data for ERNA-101, which demonstrated complete tumor elimination and 100% survival in ovarian cancer models when combined with PD-1 blockade. The discussion will also cover the potential for ERNA-101 to address immunologically “cold” tumors by reshaping the tumor microenvironment to support stronger immune responses.

For more information about ERNA-101 and the Company’s development plans, visit www.ernexatx.com

About Ernexa Therapeutics

Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative cell therapies for the treatment of advanced cancer and autoimmune diseases. Ernexa’s core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa’s allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting.

ERNA-101 is the company’s lead cell therapy product, designed to activate and regulate the immune system's response to recognize and attack cancer cells. ERNA-201 is a cell therapy product designed to target inflammation and treat autoimmune disease. The company’s initial focus is to develop ERNA-101 for the treatment of ovarian cancer.

For more information, visit www.ernexatx.com.

Media Contact
Sharon Golubchik
RAYNZ
sharon@raynzhealth.com

Investor Contact
Jenene Thomas
JTC Team, LLC
(908) 824-0775
ERNA@jtcir.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Ernexa Therapeutics (NASDAQ: ERNA) announce on May 11, 2026 about ERNA-101?

Ernexa announced a Virtual Investor KOL Connect segment and highlighted preclinical data for ERNA-101. According to Ernexa, ERNA-101 achieved complete tumor elimination and 100% survival in ovarian cancer models when combined with PD-1 blockade.

What are the key preclinical ovarian cancer results for ERNA-101 from Ernexa Therapeutics (ERNA)?

Preclinical ERNA-101 data in ovarian cancer models showed complete tumor elimination and 100% survival. According to Ernexa, these results occurred when ERNA-101 was combined with PD-1 blockade, suggesting potential to improve outcomes versus existing approaches in preclinical settings.

When is Ernexa Therapeutics’ Virtual Investor Closing Bell event for ERNA (Nasdaq: ERNA)?

The Virtual Investor Closing Bell event is scheduled for Wednesday, May 13, 2026 at 4:00 PM ET. According to Ernexa, President and CEO Sanjeev Luther and CSO Dr. Robert Pierce will provide a corporate overview and discuss ERNA-101 preclinical data.

How is Ernexa’s ERNA-101 aiming to address ovarian cancer compared with current therapies?

ERNA-101 is being developed to improve outcomes and patient experience versus existing ovarian cancer treatments. According to Ernexa, its approach targets biological differences and may help reshape the tumor microenvironment to support stronger immune responses, especially in immunologically “cold” tumors.

What is discussed in Ernexa Therapeutics’ Virtual Investor KOL Connect segment on ovarian cancer?

The KOL segment covers ovarian cancer complexity, current treatment limitations, and patient journey from diagnosis through treatment. According to Ernexa, Chief Scientific Officer Dr. Robert Pierce also outlines the evolving treatment landscape and explains how ERNA-101 could address unmet needs biologically.

How might ERNA-101 impact immunologically “cold” ovarian tumors according to Ernexa (ERNA)?

ERNA-101 may help address immunologically “cold” tumors by reshaping the tumor microenvironment. According to Ernexa, this could support stronger immune responses in ovarian cancer models, especially when ERNA-101 is used in combination with PD-1 blockade in preclinical studies.